BACKGROUND: Leucine-rich repeat kinase 2 kinase inhibitors are being vigorously pursued as potential therapeutic options; however, there is a critical need for sensitive and quantitative assays of leucine-rich repeat kinase 2 function and target engagement. OBJECTIVES: Our objective was to compare collection and storage protocols for peripheral blood mononuclear cells, and to determine the optimal conditions for downstream analyses of leucine-rich repeat kinase 2 in PD cohorts. METHODS: Here, we describe enzyme-linked immunosorbent assay-based assays capable of detecting multiple aspects of leucine-rich repeat kinase 2 function at endogenous levels in human tissues. RESULTS: In peripheral blood mononuclear cells from both healthy and affected carriers of the G2019S mutation in leucine-rich repeat kinase 2, we report, for the first time, significantly elevated in vitro kinase activity, while detecting a significant increase in pS935/leucine-rich repeat kinase 2 in idiopathic PD patients. CONCLUSIONS: Quantitative assays such as these described here could potentially uncover specific markers of leucine-rich repeat kinase 2 function that are predictive of disease progression, aid in patient stratification, and be a critical component of upcoming clinical trials.
BACKGROUND: Leucine-rich repeat kinase 2 kinase inhibitors are being vigorously pursued as potential therapeutic options; however, there is a critical need for sensitive and quantitative assays of leucine-rich repeat kinase 2 function and target engagement. OBJECTIVES: Our objective was to compare collection and storage protocols for peripheral blood mononuclear cells, and to determine the optimal conditions for downstream analyses of leucine-rich repeat kinase 2 in PD cohorts. METHODS: Here, we describe enzyme-linked immunosorbent assay-based assays capable of detecting multiple aspects of leucine-rich repeat kinase 2 function at endogenous levels in human tissues. RESULTS: In peripheral blood mononuclear cells from both healthy and affected carriers of the G2019S mutation in leucine-rich repeat kinase 2, we report, for the first time, significantly elevated in vitro kinase activity, while detecting a significant increase in pS935/leucine-rich repeat kinase 2 in idiopathic PD patients. CONCLUSIONS: Quantitative assays such as these described here could potentially uncover specific markers of leucine-rich repeat kinase 2 function that are predictive of disease progression, aid in patient stratification, and be a critical component of upcoming clinical trials.
Authors: Kyle B Fraser; Mark S Moehle; João P L Daher; Philip J Webber; Jeri Y Williams; Carrie A Stewart; Talene A Yacoubian; Rita M Cowell; Terje Dokland; Tong Ye; Dongquan Chen; Gene P Siegal; Robert A Galemmo; Elpida Tsika; Darren J Moore; David G Standaert; Kyoko Kojima; James A Mobley; Andrew B West Journal: Hum Mol Genet Date: 2013-07-25 Impact factor: 6.150
Authors: Kyle B Fraser; Ashlee B Rawlins; Rachel G Clark; Roy N Alcalay; David G Standaert; Nianjun Liu; Andrew B West Journal: Mov Disord Date: 2016-10 Impact factor: 10.338
Authors: Farzaneh Atashrazm; Deborah Hammond; Gayathri Perera; Marc F Bolliger; Elie Matar; Glenda M Halliday; Birgitt Schüle; Simon J G Lewis; R Jeremy Nichols; Nicolas Dzamko Journal: Mov Disord Date: 2018-12-30 Impact factor: 10.338
Authors: Özge Karayel; Francesca Tonelli; Sebastian Virreira Winter; Phillip E Geyer; Ying Fan; Esther M Sammler; Dario R Alessi; Martin Steger; Matthias Mann Journal: Mol Cell Proteomics Date: 2020-06-29 Impact factor: 5.911
Authors: Shalini Padmanabhan; Thomas A Lanz; Donal Gorman; Michele Wolfe; Alison Joyce; Carlos Cabrera; Rosemary Lawrence-Henderson; Najah Levers; Neal Joshi; Thong C Ma; Christopher Liong; Sushma Narayan; Roy N Alcalay; Samantha J Hutten; Marco A S Baptista; Kalpana Merchant Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568
Authors: Sven H Schmidt; Matthias J Knape; Daniela Boassa; Natascha Mumdey; Alexandr P Kornev; Mark H Ellisman; Susan S Taylor; Friedrich W Herberg Journal: Proc Natl Acad Sci U S A Date: 2019-07-10 Impact factor: 11.205
Authors: Roy N Alcalay; Frank Hsieh; Elizabeth Tengstrand; Shalini Padmanabhan; Marco Baptista; Caitlin Kehoe; Sushma Narayan; Amelia K Boehme; Kalpana Merchant Journal: Mov Disord Date: 2019-09-10 Impact factor: 10.338
Authors: Maria Kedariti; Emanuele Frattini; Pascale Baden; Susanna Cogo; Laura Civiero; Elena Ziviani; Gianluca Zilio; Federico Bertoli; Massimo Aureli; Alice Kaganovich; Mark R Cookson; Leonidas Stefanis; Matthew Surface; Michela Deleidi; Alessio Di Fonzo; Roy N Alcalay; Hardy Rideout; Elisa Greggio; Nicoletta Plotegher Journal: NPJ Parkinsons Dis Date: 2022-07-19
Authors: Sebastian Virreira Winter; Ozge Karayel; Maximilian T Strauss; Shalini Padmanabhan; Matthew Surface; Kalpana Merchant; Roy N Alcalay; Matthias Mann Journal: EMBO Mol Med Date: 2021-01-22 Impact factor: 12.137